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Background
Brazil is a tropical country that shows a great biodiversity
and is a rich source of new allergens especially from foods.
Exotic tropical fruits and plants are highly consumed in
the country and due to globalization these products are
being exported worldwide. We have recently described the
first manioc allergen Man e 5 that cross-reacts with Hev b
5 from latex. There are more than 70 products made up
manioc starch such as drugs, soaps and fabrics and manioc
allergic patients present from mild to severe reactions.
Methods
ELISA and ISAC inhibition assays using manioc extract
and rMan e 5. Amongst manioc allergic patients we
selected a Brazilian woman that lives in North region
where manioc is consumed in a daily diet for an oral
immunotherapy (OIT) protocol. The patient is a hairdres-
ser, 48 years old, IgE mediated latex allergy presenting
cough, sneeze and cutaneous itching. Six years ago she
started to have immediate symptoms of urticaria, oral itch-
ing and cough after eating different foods prepared with
manioc, but more recently she began to present allergic
manifestations after inhalatory exposition to manioc
starch. Patient was then submitted to OIT with manioc
starch solubilized in 10mg/mL. Immunotherapy was
divided in two parts: induction and maintenance. In the
first phase dose was weekly increased starting with 0.1mL
of a 10mg/mL until reaching an amount of 10g of manioc
starch. At this point the patient was submitted to oral
provocation with 100g of manioc. For maintenance it was
indicated daily ingestion of foods prepared with manioc.
Clinical evaluation, skin tests and IgE levels after 1 and 6
months were performed.
Results
Inhibition assays showed that rMan e 5 is not the only
manioc allergen and that there is a molecule in manioc
cross-reacting with Hev b 6. After OIT patient presented a
decrease of the wheal in pricktest (10 to 4mm) and also
IgE levels to latex diminished. Oral provocation was nega-
tive. Reactions during treatment were mild (abdominal
pain and oral itching) and solved spontaneously or using
antihistaminic. After two years under maintenance patient
keeps asymptomatic eating manioc without restrictions.
Conclusion
There are at least two manioc allergens cross-reacting
with latex. OIT was proved to be safe and efficient in
this case allowing free ingestion of manioc. Levels of
latex IgE also decreased after treatment. Knowledge of
single allergens is important for diagnosis and also to
monitor therapeutic success.
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